Monica M. Lahra
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Monica M. Lahra has a total of 107 co-authors. Here are the top co-authors by number of shared publications:
Tiffany Hogan
NSW Health Pathology, World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology, Prince of Wales Hospital, Randwick, NSW 2031, Australia
8 shared publicationsSebastiaan Van Hal
NSW Health Pathology, Molecular Microbiology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia
7 shared publicationsSiobhan Hurley
NSW Health Pathology, The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia
6 shared publicationsSebastiaan J van Hal
NSW Health Pathology, Microbiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia; Central Clinical School, University of Sydney, Sydney, New South Wales, Australia
5 shared publicationsTiffany R Hogan
NSW Health Pathology, The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia
4 shared publicationsCr Robert George
NSW Health Pathology, John Hunter Hospital, Newcastle, 2300, NSW Australia.
3 shared publications
Latest Publications
- Open Access
- 16 June 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Australian Gonococcal Surveillance Program, 1 October to 31 December 2025
The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 October to 31 December 2025.
- 16 June 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Open AccessAustralian Gonococcal Surveillance Program, 1 October to 31 December 2025
The Australian National Neisseria Network (NNN) comprises reference laboratories in each state and territory that report data on antimicrobial susceptibility testing to an agreed group of antimicrobial agents for the Australian Gonococcal Surveillance Programme (AGSP). The AGSP data are presented quarterly in tabulated form, as well as in the AGSP annual report. This report presents national gonococcal antimicrobial resistance surveillance data from 1 October to 31 December 2025.
- Open Access
- 16 June 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Meningococcal Surveillance Australia: Reporting period 1 July to 30 September 2025
The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.
- 16 June 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Open AccessMeningococcal Surveillance Australia: Reporting period 1 July to 30 September 2025
The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.
- Open Access
- 16 June 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Meningococcal Surveillance Australia: Reporting period 1 October to 31 December 2025
The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.
- 16 June 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Open AccessMeningococcal Surveillance Australia: Reporting period 1 October to 31 December 2025
The reference laboratories of the Australian Meningococcal Surveillance Programme (AMSP) report data on the number of cases of invasive meningococcal disease (IMD) confirmed by laboratory testing using culture and molecular based techniques. Data contained in quarterly reports are restricted to a description of case numbers of IMD by jurisdiction and serogroup, where known and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. A full analysis of laboratory confirmations of IMD in each calendar year are contained in the AMSP annual reports.
- Open Access
- 24 March 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Australian Gonococcal Surveillance Program, 1 July to 30 September 2025
The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin and tetracycline are included in the AGSP Annual Report. Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in Australia. Historically, there were substantial geographic differences in susceptibility patterns across the country, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin was recommended. However, since January 2023, increasing reports of penicillin-resistant N. gonorrhoeae in the Northern Territory have changed treatment recommendations to align with the majority of Australia.1 Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP is supported by a programme-specific quality assurance process.
- 24 March 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Open AccessAustralian Gonococcal Surveillance Program, 1 July to 30 September 2025
The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin and tetracycline are included in the AGSP Annual Report. Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in Australia. Historically, there were substantial geographic differences in susceptibility patterns across the country, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin was recommended. However, since January 2023, increasing reports of penicillin-resistant N. gonorrhoeae in the Northern Territory have changed treatment recommendations to align with the majority of Australia.1 Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP is supported by a programme-specific quality assurance process.
- Open Access
- 24 February 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Maternal vaginal colonisation with Neisseria meningitidis serogroup B and late onset neonatal invasive meningococcal disease
Here we report a case of late onset neonatal invasive meningococcal disease that was vertically transmitted, with maternal vaginal swab at the time of delivery and neonatal cerebrospinal fluid culture positive for Neisseria meningitidis. Whole genome sequencing of meningococcal isolates in the neonatal cerebrospinal fluid and maternal vaginal found both Men-B ST-2506 (clonal complex 32) and identical (1 SNP difference on split kmer analysis).
- 24 February 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Open AccessMaternal vaginal colonisation with Neisseria meningitidis serogroup B and late onset neonatal invasive meningococcal disease
Here we report a case of late onset neonatal invasive meningococcal disease that was vertically transmitted, with maternal vaginal swab at the time of delivery and neonatal cerebrospinal fluid culture positive for Neisseria meningitidis. Whole genome sequencing of meningococcal isolates in the neonatal cerebrospinal fluid and maternal vaginal found both Men-B ST-2506 (clonal complex 32) and identical (1 SNP difference on split kmer analysis).
- Open Access
- 28 January 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Meningococcal Surveillance Australia: Reporting period 1 April to 30 June 2025
The reference laboratories of the Australian National Neisseria Network report data on invasive meningococcal disease (IMD) confirmed by culture and/or molecular techniques for the Australian Meningococcal Surveillance Programme (AMSP). Culture-positive cases and molecular-based diagnoses are defined as IMD by the Communicable Diseases Network Australia National Guidelines for Public Health Units.1 Data contained in the quarterly reports are restricted to a description of the number of cases by jurisdiction and serogroup, when known. The content of the quarterly reports was expanded in 2024 to include antimicrobial resistance (AMR) data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. IMD AMR data was previously only reported annually in the AMSP Annual Report. The AMSP has a programme-specific quality assurance process. Some minor corrections to data in Table 1 may be made in subsequent reports if additional data are received. IMD notifications in Australia for the first six months of 2025 were consistent with the corresponding period of 2024 (Table 1),2 but lower than the 85 IMD notifications reported at quarter two year-to-date (ytd) in 2019 (prior to the SARS-CoV-2 pandemic).3 In quarter two 2025 ytd, there were 59 notifications of IMD nationally, of which 55/59 (93%) had the serogroup determined at the time of reporting. Notably, the predominance of N. meningitidis serogroup B (MenB) IMD continued in 2025, accounting for 82% of notifications (45/55) ytd, higher than reported in quarter 1 2025 (72%). In contrast, between 2019 and 2021, the proportion of IMD attributable to MenB was 50–62%.4 The number of notifications of IMD attributed to MenW and MenY remain small, and no further MenA or MenC IMD cases were reported in Australia in quarter two of 2025 (Table 1). Antimicrobial susceptibility testing data, on the 39 IMD diagnosed by culture ytd, detected two penicillin-resistant isolates, one from Western Australia (quarter one) and one from Victoria (quarter 2), both identified as MenB IMD. All 39 IMD isolates were susceptible to ceftriaxone and there was no resistance detected to ciprofloxacin and rifampicin. A full analysis of laboratory-confirmed cases of IMD in each calendar year is contained in the AMSP annual report published in Communicable Diseases Intelligence.
- 28 January 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Open AccessMeningococcal Surveillance Australia: Reporting period 1 April to 30 June 2025
The reference laboratories of the Australian National Neisseria Network report data on invasive meningococcal disease (IMD) confirmed by culture and/or molecular techniques for the Australian Meningococcal Surveillance Programme (AMSP). Culture-positive cases and molecular-based diagnoses are defined as IMD by the Communicable Diseases Network Australia National Guidelines for Public Health Units.1 Data contained in the quarterly reports are restricted to a description of the number of cases by jurisdiction and serogroup, when known. The content of the quarterly reports was expanded in 2024 to include antimicrobial resistance (AMR) data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. IMD AMR data was previously only reported annually in the AMSP Annual Report. The AMSP has a programme-specific quality assurance process. Some minor corrections to data in Table 1 may be made in subsequent reports if additional data are received. IMD notifications in Australia for the first six months of 2025 were consistent with the corresponding period of 2024 (Table 1),2 but lower than the 85 IMD notifications reported at quarter two year-to-date (ytd) in 2019 (prior to the SARS-CoV-2 pandemic).3 In quarter two 2025 ytd, there were 59 notifications of IMD nationally, of which 55/59 (93%) had the serogroup determined at the time of reporting. Notably, the predominance of N. meningitidis serogroup B (MenB) IMD continued in 2025, accounting for 82% of notifications (45/55) ytd, higher than reported in quarter 1 2025 (72%). In contrast, between 2019 and 2021, the proportion of IMD attributable to MenB was 50–62%.4 The number of notifications of IMD attributed to MenW and MenY remain small, and no further MenA or MenC IMD cases were reported in Australia in quarter two of 2025 (Table 1). Antimicrobial susceptibility testing data, on the 39 IMD diagnosed by culture ytd, detected two penicillin-resistant isolates, one from Western Australia (quarter one) and one from Victoria (quarter 2), both identified as MenB IMD. All 39 IMD isolates were susceptible to ceftriaxone and there was no resistance detected to ciprofloxacin and rifampicin. A full analysis of laboratory-confirmed cases of IMD in each calendar year is contained in the AMSP annual report published in Communicable Diseases Intelligence.
- Open Access
- 28 January 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Australian Gonococcal Surveillance Program, 1 April to 30 June 2025
The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin and tetracycline are included in the AGSP Annual Report. Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in Australia. Historically, there were substantial geographic differences in susceptibility patterns across the country, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin was recommended. However, since January 2023, increasing reports of penicillin-resistant N. gonorrhoeae in the Northern Territory have changed treatment recommendations to align with the majority of Australia.1 Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.
- 28 January 2026
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 50
Open AccessAustralian Gonococcal Surveillance Program, 1 April to 30 June 2025
The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin and tetracycline are included in the AGSP Annual Report. Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in Australia. Historically, there were substantial geographic differences in susceptibility patterns across the country, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin was recommended. However, since January 2023, increasing reports of penicillin-resistant N. gonorrhoeae in the Northern Territory have changed treatment recommendations to align with the majority of Australia.1 Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP has a programme-specific quality assurance process.
- Open Access
- 19 January 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (1) , 001623
Gene exchange between Neisseria meningitidis and Neisseria gonorrhoeae
Genetic exchange between Neisseria meningitidis (NM) and Neisseria gonorrhoeae (NG) has not been well studied. This study aimed to investigate evidence of genetic exchanges between these two species. All coincident paired NM and NG isolates cultured from pharyngeal swabs collected from a sexual health clinic in Sydney in 2021 underwent whole-genome sequencing. A gene-by-gene analysis of the 47 NM–NG pairs identified 184 instances where the ancestry of the gene revealed intermixing between the two species. Incorporating the gene phylogenies demonstrated that these events occurred across a wide range of timeframes. At the nucleotide level, 91 genes were found where paired isolates harboured identical sequences. Notably, one instance of unequivocal recent gene transfer events between the paired pharynx isolates was observed. This work provides new insights into the evolutionary dynamics of these bacteria and highlights the importance of genetic exchange in populations with high rates of pharyngeal gonorrhoea. The clinical implications of such exchanges call for continued vigilance and research to address the challenges posed by these bacteria.
- 19 January 2026
- Published by Microbiology Society in Microbial Genomics
- Vol. 12 (1) , 001623
Open AccessGene exchange between Neisseria meningitidis and Neisseria gonorrhoeae
Genetic exchange between Neisseria meningitidis (NM) and Neisseria gonorrhoeae (NG) has not been well studied. This study aimed to investigate evidence of genetic exchanges between these two species. All coincident paired NM and NG isolates cultured from pharyngeal swabs collected from a sexual health clinic in Sydney in 2021 underwent whole-genome sequencing. A gene-by-gene analysis of the 47 NM–NG pairs identified 184 instances where the ancestry of the gene revealed intermixing between the two species. Incorporating the gene phylogenies demonstrated that these events occurred across a wide range of timeframes. At the nucleotide level, 91 genes were found where paired isolates harboured identical sequences. Notably, one instance of unequivocal recent gene transfer events between the paired pharynx isolates was observed. This work provides new insights into the evolutionary dynamics of these bacteria and highlights the importance of genetic exchange in populations with high rates of pharyngeal gonorrhoea. The clinical implications of such exchanges call for continued vigilance and research to address the challenges posed by these bacteria.
- Open Access
- 18 November 2025
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 49
Australian Gonococcal Surveillance Programme Annual Report, 2024
The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in Neisseria gonorrhoeae (NG) for more than 40 years through the system of jurisdictional Neisseria reference laboratories, the National Neisseria Network (NNN). In 2024, a total of 10,702 isolates across Australia, from public and private sectors, were tested for in vitro antimicrobial susceptibility by standardised methods. In 2024, the AGSP captured antimicrobial susceptibility data for 24.0% of all gonococcal infection notifications nationally. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2024, of NG isolates tested, 0.51% (55/10,702) met the World Health Organization (WHO) criterion for decreased susceptibility (DS) to ceftriaxone, defined as a minimum inhibitory concentration (MIC) ≥ 0.125 mg/L. This proportion of isolates meeting the ceftriaxone DS criterion was more than double that reported in 2023 (0.22%), with the majority from New South Wales and Victoria. Genomic analysis indicated that 76.4% of these isolates (42/55) possessed the mosaic penA 60.001 allele, the key target associated with ceftriaxone resistance. Resistance to azithromycin was reported in 4.6% of NG isolates nationally, proportionally stable since 2019. Of these, 0.43% (46/10,702) exhibited high-level resistance to azithromycin (MIC value ≥ 256 mg/L), with cases reported across Australia, predominantly in New South Wales and Victoria. There were nine isolates in 2024 that had an extensively drug-resistant (XDR) phenotype: i.e., displaying both high-level resistance to azithromycin and decreased susceptibility to ceftriaxone (MIC ≥ 0.125 mg/L). When added to the five XDR isolates reported during 2022–2023, this brings the total to 14 XDR NG isolates reported in Australia since 2022. Genomic analyses of the nine XDR isolates reported in 2024 indicated the presence of the mosaic penA 60.001 allele and identified the isolates as belonging to sequence type (ST) 16406, consistent with recent reports from Europe, England and Southeast Asia of an increase in detection since 2022. Travel information, where available, indicates most were associated with travel or contact in the Asia-Pacific region. In 2024, penicillin resistance was found in 30.8% of gonococcal isolates, and ciprofloxacin resistance in 57.5% of isolates where tested, although there was variation by jurisdiction particularly in remote settings, where acquisition of cultures for antimicrobial susceptibility testing is low. Tetracycline resistance has been reported in the AGSP in recent years, coincident with increasing use of doxycycline post-exposure prophylaxis for syphilis and chlamydia. Nationally 35.2% of NG isolates in 2024 were tetracycline resistant, with variation by jurisdiction. No isolates were resistant to spectinomycin; data for gentamicin, whilst no breakpoints are defined, are reported by the AGSP as these data are reportable to the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS). The emergence of antimicrobial resistant NG in Australia has largely occurred through importation, spread and local transmission. In 2024, in Australia and overseas, increased detection of drug-resistant NG isolates is of significant concern as the threat for the future of the current recommended therapeutic agents is increasingly evident, and no ideal alternate therapeutic agent has been identified. Disease prevention strategies under investigation for the future include the MenB-4C vaccine, designed to protect against meningococcal disease but shown to be moderately effective against gonorrhoea in various populations, although the duration of protection is uncertain. The AGSP continues to monitor antimicrobial resistance and to identify emerging resistant clones by enhanced surveillance approaches, to inform strategies for disease management and treatment of gonorrhoea in Australia.
- 18 November 2025
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 49
Open AccessAustralian Gonococcal Surveillance Programme Annual Report, 2024
The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in Neisseria gonorrhoeae (NG) for more than 40 years through the system of jurisdictional Neisseria reference laboratories, the National Neisseria Network (NNN). In 2024, a total of 10,702 isolates across Australia, from public and private sectors, were tested for in vitro antimicrobial susceptibility by standardised methods. In 2024, the AGSP captured antimicrobial susceptibility data for 24.0% of all gonococcal infection notifications nationally. The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2024, of NG isolates tested, 0.51% (55/10,702) met the World Health Organization (WHO) criterion for decreased susceptibility (DS) to ceftriaxone, defined as a minimum inhibitory concentration (MIC) ≥ 0.125 mg/L. This proportion of isolates meeting the ceftriaxone DS criterion was more than double that reported in 2023 (0.22%), with the majority from New South Wales and Victoria. Genomic analysis indicated that 76.4% of these isolates (42/55) possessed the mosaic penA 60.001 allele, the key target associated with ceftriaxone resistance. Resistance to azithromycin was reported in 4.6% of NG isolates nationally, proportionally stable since 2019. Of these, 0.43% (46/10,702) exhibited high-level resistance to azithromycin (MIC value ≥ 256 mg/L), with cases reported across Australia, predominantly in New South Wales and Victoria. There were nine isolates in 2024 that had an extensively drug-resistant (XDR) phenotype: i.e., displaying both high-level resistance to azithromycin and decreased susceptibility to ceftriaxone (MIC ≥ 0.125 mg/L). When added to the five XDR isolates reported during 2022–2023, this brings the total to 14 XDR NG isolates reported in Australia since 2022. Genomic analyses of the nine XDR isolates reported in 2024 indicated the presence of the mosaic penA 60.001 allele and identified the isolates as belonging to sequence type (ST) 16406, consistent with recent reports from Europe, England and Southeast Asia of an increase in detection since 2022. Travel information, where available, indicates most were associated with travel or contact in the Asia-Pacific region. In 2024, penicillin resistance was found in 30.8% of gonococcal isolates, and ciprofloxacin resistance in 57.5% of isolates where tested, although there was variation by jurisdiction particularly in remote settings, where acquisition of cultures for antimicrobial susceptibility testing is low. Tetracycline resistance has been reported in the AGSP in recent years, coincident with increasing use of doxycycline post-exposure prophylaxis for syphilis and chlamydia. Nationally 35.2% of NG isolates in 2024 were tetracycline resistant, with variation by jurisdiction. No isolates were resistant to spectinomycin; data for gentamicin, whilst no breakpoints are defined, are reported by the AGSP as these data are reportable to the WHO Global Antimicrobial Resistance and Use Surveillance System (GLASS). The emergence of antimicrobial resistant NG in Australia has largely occurred through importation, spread and local transmission. In 2024, in Australia and overseas, increased detection of drug-resistant NG isolates is of significant concern as the threat for the future of the current recommended therapeutic agents is increasingly evident, and no ideal alternate therapeutic agent has been identified. Disease prevention strategies under investigation for the future include the MenB-4C vaccine, designed to protect against meningococcal disease but shown to be moderately effective against gonorrhoea in various populations, although the duration of protection is uncertain. The AGSP continues to monitor antimicrobial resistance and to identify emerging resistant clones by enhanced surveillance approaches, to inform strategies for disease management and treatment of gonorrhoea in Australia.
- Open Access
- 18 November 2025
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 49
Australian Meningococcal Surveillance Programme Annual Report, 2024
In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). When compared to 2023, the number of IMD notifications in 2024 decreased by 5% to 136. IMD was confirmed by laboratory testing in 136/136 (100%) of 2024 IMD cases, with 63% (86/136) diagnosed by bacterial culture and 37% (50/136) by nucleic acid amplification testing. The serogroup was determined for 96% of laboratory-confirmed cases (130/136): serogroup B (MenB) accounted for 84% of infections (109/130); MenY for 14% (18/130); MenW for 1.5% (2/130) and MenC for 0.8% (1/130). Finetyping was available on 71% of the cases for which the serogroup was determined (92/130). In MenB isolates, 21 porA types were detected, the most prevalent of which were P1.7-2,4 (38%; 29/76) and P1.7,16-26 (11%; 8/76). In MenY infections, 6 porA types were detected, with P1.5-1,10-1 the dominant porA type (60%; 9/15); where typed, this was of multilocus sequence type MLST (ST) 1655 and from clonal complex 23 (8/9). One of the two MenW isolates in 2024 was finetyped and identified as porA type P1.5,2, MLST (ST) 11 and belonging to the clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. The MenC isolate was not typed. Peaks of IMD occurred in children aged less than 5 years, and in those aged 15–24 years, accounting for 20% (27/136) and 28% (38/136) of laboratory-confirmed cases respectively. In children aged under 5 years, 92% (24/26) of IMD was MenB; in those aged 15–24 years, 94% (33/35) of IMD was MenB, with serogroup not determined for one case in those aged < 5 years and three cases aged 15–24 years. IMD was reported in all age groups: < 5 years (20%; 27/136); 5–9 years (6%; 8/136); 10–14 years (5%; 7/136); 15–24 years (28%; 38/136); 25–44 years (12%; 16/136); 45–64 years (18%; 25/136); and in those aged 65 years and older (11%; 15/136). Whilst MenB predominated in all age groups, the majority of MenY IMD cases were reported in adults aged 45 years and older (14/18; 78%). All cultured IMD isolates (n = 86) had antimicrobial susceptibility testing performed with ceftriaxone and penicillin. Minimum inhibitory concentration (MIC) values were reported using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 7% (6/86) were defined as penicillin resistant (MIC value, ≥ 0.5mg/L); 60% (52/86) had intermediate susceptibility to penicillin (MIC values, 0.125 and 0.25 mg/L); and 33% (28/86) were susceptible to penicillin (MIC values, ≤ 0.064 mg/L). All isolates tested susceptible to ceftriaxone, ciprofloxacin and rifampicin.
- 18 November 2025
- Published by Australian Centre for Disease Control in Communicable Diseases Intelligence
- Vol. 49
Open AccessAustralian Meningococcal Surveillance Programme Annual Report, 2024
In Australia, both probable and laboratory-confirmed cases of invasive meningococcal disease (IMD) are reported to the National Notifiable Diseases Surveillance System (NNDSS). When compared to 2023, the number of IMD notifications in 2024 decreased by 5% to 136. IMD was confirmed by laboratory testing in 136/136 (100%) of 2024 IMD cases, with 63% (86/136) diagnosed by bacterial culture and 37% (50/136) by nucleic acid amplification testing. The serogroup was determined for 96% of laboratory-confirmed cases (130/136): serogroup B (MenB) accounted for 84% of infections (109/130); MenY for 14% (18/130); MenW for 1.5% (2/130) and MenC for 0.8% (1/130). Finetyping was available on 71% of the cases for which the serogroup was determined (92/130). In MenB isolates, 21 porA types were detected, the most prevalent of which were P1.7-2,4 (38%; 29/76) and P1.7,16-26 (11%; 8/76). In MenY infections, 6 porA types were detected, with P1.5-1,10-1 the dominant porA type (60%; 9/15); where typed, this was of multilocus sequence type MLST (ST) 1655 and from clonal complex 23 (8/9). One of the two MenW isolates in 2024 was finetyped and identified as porA type P1.5,2, MLST (ST) 11 and belonging to the clonal complex 11, the hypervirulent strain reported in outbreaks in Australia and overseas. The MenC isolate was not typed. Peaks of IMD occurred in children aged less than 5 years, and in those aged 15–24 years, accounting for 20% (27/136) and 28% (38/136) of laboratory-confirmed cases respectively. In children aged under 5 years, 92% (24/26) of IMD was MenB; in those aged 15–24 years, 94% (33/35) of IMD was MenB, with serogroup not determined for one case in those aged < 5 years and three cases aged 15–24 years. IMD was reported in all age groups: < 5 years (20%; 27/136); 5–9 years (6%; 8/136); 10–14 years (5%; 7/136); 15–24 years (28%; 38/136); 25–44 years (12%; 16/136); 45–64 years (18%; 25/136); and in those aged 65 years and older (11%; 15/136). Whilst MenB predominated in all age groups, the majority of MenY IMD cases were reported in adults aged 45 years and older (14/18; 78%). All cultured IMD isolates (n = 86) had antimicrobial susceptibility testing performed with ceftriaxone and penicillin. Minimum inhibitory concentration (MIC) values were reported using Clinical Laboratory Standards Institute (CLSI) interpretative criteria: 7% (6/86) were defined as penicillin resistant (MIC value, ≥ 0.5mg/L); 60% (52/86) had intermediate susceptibility to penicillin (MIC values, 0.125 and 0.25 mg/L); and 33% (28/86) were susceptible to penicillin (MIC values, ≤ 0.064 mg/L). All isolates tested susceptible to ceftriaxone, ciprofloxacin and rifampicin.